Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.
Impact of Troponin Performance on Patient CareLinda C, Rogers PhD, DABCC, FACB
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 2 December 2015 A91DX-CAI-151429-UC1-4A00
Agenda
• Introduction• Diagnosis of MI
• Guidelines• Troponin
• Assay differences• Classification of troponin assays
• Guideline acceptable vs clinically usable assays• Importance in testing protocols• Recent studies and comparison
• Definition of high sensitive troponin assays• Guideline acceptable vs high sensitive assays
• Recent studies and comparison
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 3 December 2015 A91DX-CAI-151429-UC1-4A00
Global Burden of Cardiovascular Disease
occur in low andmiddle income countries
80%23.3 MillionCVD deaths globally
2030
cause of death in the industrialized worldNumber One
of all deaths globally arefrom cardiovascular disease
31%2012
http://www.who.int/mediacentre/factsheets/fs317/en/
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 4 December 2015 A91DX-CAI-151429-UC1-4A00
U.S. Hospitals Are Facing Increased Pressures
PatientOutcomes
FinancialPressure
Healthcare Reformand Quality Metrics
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 5 December 2015 A91DX-CAI-151429-UC1-4A00
ED Chest Pain Evaluation
Is the patient having an MI?
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 6 December 2015 A91DX-CAI-151429-UC1-4A00
Acute-care Diagnostic Tests for AMI
Signs andSymptoms
Electrocardiogram
Imaging
CardiacBiomarkers
Clinical history, risk factors, and physical exam
Thygesen K, et al. Eur Heart J 2012;33:2551-67.Amsterdam EA, et al. Circulation 2014;130:e344-426
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 7 December 2015 A91DX-CAI-151429-UC1-4A00
Chest Pain due to myocardial reasons:
ACS or AMI or other cardiac damage
Chest Pain
Pulmonary embolismAortic dissection
Aortic aneurysm
Pneumonia
Sickle cell Anemia
Musculoskeletal injury
Pneumothorax
Vascular
Orthopedic/infectious
Chest Pain: Is Cardiac Damage Related to Ischemia?
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 8 December 2015 A91DX-CAI-151429-UC1-4A00
Cardiac Damage Is Often Not ACS-related
ACS or MI Other Cardiac Damage
Chest Pain
Adapted from Hamm CW, et al. Eur Heart J 2011;32:2999-3054.
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 9 December 2015 A91DX-CAI-151429-UC1-4A00
Acute Coronary Syndromes
https://www.clinicalkey.com/topics/gerontology/acute-myocardial-infarction.html
STEMI NSTEMI
UnstableAngina
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 10 December 2015 A91DX-CAI-151429-UC1-4A00
A typical situation:§ acute chest pain§ electrocardiogram is non-diagnostic§ low risk for myocardial infarction§moderate risk for unstable angina
The most critical questions:§ Should the patient be sent home?§ Should the patient be admitted to the cath
lab?
The ED Physician’s Dilemma . . .
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 11 December 2015 A91DX-CAI-151429-UC1-4A00
Biomarkers Are Critical for Diagnosing the Majority of Patients
Cardiac troponin (cTn)
Two types: cTnI and cTnT
Creatine kinase
CK-MBMyoglobin
Thygesen K, et al. Eur Heart J 2012;33:2551-67.Amsterdam EA, et al. Circulation 2014;130:e344-426.
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 12 December 2015 A91DX-CAI-151429-UC1-4A00
Milestones in Myocardial Infarction Guideline Developments
2000 2012
• Integrates new knowledge.
• Small myocardial injury can be detected usingsensitive assay or imaging.
• Rising or falling kinetics helps discriminateacute from chronic illness.
2007
Thygesen, et al. Eur Heart J. 2012;33:2551-67.
2000: cTn is the preferred biomarker.Values >99th percentile with an assaythat has <10%CV at the 99th percentilerecommended.
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 13 December 2015 A91DX-CAI-151429-UC1-4A00
3rd Universal Definition of MI (2012)
Each of the five types defines a value for cTn for a diagnosis.
Cardiac troponin (cTn) critical to the identification of NSTEMI.
A changing cTn pattern aids differentiation of AMI from othercauses of chronic cTn elevation.
As cTn is not standardized, the 99th percentile of the assay URLis used.
Five different types of MI are defined.
Thygesen K, et al. Eur Heart J 2012;33:2551-67.
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 14 December 2015 A91DX-CAI-151429-UC1-4A00
Guideline Acceptable: The 99th Percentile Is Determined Using an ApparentlyHealthy Reference Population
100%
A CV of <10% at the99th percentile improves
the ability to assess change.
99% correct(no pathology)
%Po
pula
tion
Dis
trib
utio
n
cTn LevelHealthy AMI or Other Pathology
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 15 December 2015 A91DX-CAI-151429-UC1-4A00
Type 1 MI: Plaque Rupture, Ulceration, Fissuring,Erosion, or Dissection with Resulting Thrombus
Thygesen, et al. Eur Heart J. 2012:33;2251-67.
cTn >99th percentile and showing achanging pattern
Ischemia producescardiac damage
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 16 December 2015 A91DX-CAI-151429-UC1-4A00
Type 2 MI: Ischemic Imbalance
Vasospasm or endothelium dysfunction
Fixed atherosclerosis and supply-demand imbalance
Supply-demand imbalance
Demand
SupplyThygesen, et al. Eur Heart J. 2012:33;2251-67.
cTn >99th percentile and showing achanging pattern
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 17 December 2015 A91DX-CAI-151429-UC1-4A00
Admission
Working Diagnosis
ECG
Biochemistry
Diagnosis
Chest Pain
Acute Coronary Syndrome
PersistentST Elevation
ST/TAbnormalities
Normal orUndetermined ECG
STEMI (12%)
TroponinRise/Fall
TroponinNormal
NSTEMI (18%) UnstableAngina (70%)
AMI Diagnostic Algorithm
Adapted from Hamm CW, et al. Eur Heart J 2011;32:2999-3054.
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 18 December 2015 A91DX-CAI-151429-UC1-4A00
Troponin Controls Myofibril Contraction
TropomyosinActin
cTnIcTnT
cTnC
Myofibril
Troponin
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 19 December 2015 A91DX-CAI-151429-UC1-4A00
Adapted from Anderson, et al. J Am Coll Cardiol. 2007;50:e1-e157.
Release of Cardiac TnI and TnT Have the Same Profile
Car
diac
mar
kerc
once
ntra
tion
(mul
tiple
sof
UR
L)
Time (days)
00 1 2 3 4 5 6 7 14
50
100cTnI
cTnT
Primarily I:C complex and complete T:I:C complex
Primarily free TnT, T:I:C trimeric complex, and some smallerimmunoreactive fragments
Majority of cTnT is associated with the intact filament
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 20 December 2015 A91DX-CAI-151429-UC1-4A00
Why do troponin assays differ numerically?
• Standardization• No universal standard is currently available• Manufacturers use their own standards
• Capture antibodies differ among manufacturers
• Detection antibodies differ among manufacturers
• Troponin is degraded into multiple fragments• A troponin assay may or may not detect different fragments
• Numeric values have no relationship to sensitivity of the assay
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 21 December 2015 A91DX-CAI-151429-UC1-4A00
Troponin I Molecule
Immunoassays use antibodies to bind and capture the troponin moleculeTroponin is degraded in the circulation, therefore the best assay design is totarget the stable region
Antibody pair bindsto stable region of troponin molecule
1 30 110 209N-terminal C-terminal
ProteasesProteases ProteasesProteases
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 22 December 2015 A91DX-CAI-151429-UC1-4A00
[24-40]
[27-39]
[27-40*]
NT
CardiacSpecific Region Most Stable Region
10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 170 180 190 200
Access (Beckman Coulter)
AxSYM and Architect (Abbott)[41-49]
Centaur (Siemens)
Liaison (Byk-Sangtec Diagnostica)
[41-49]
[20-39] [87-91]
[41-49] [87-91]
[80-110]
CT
polyclonal antibody monoclonal antibody
PhosphorylationSer23, Ser24
HeparinInterference
OxidationCys80, Cys97
Auto-antibodyInterference
Assayantibody regions
Region of proteolytic degradation
Examples of Assay Antibody detection for Troponin I
Vista (Siemens)[27-32] [41-56]
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 23 December 2015 A91DX-CAI-151429-UC1-4A00
Adapted from Apple et al Clin Chem 2012;58:1574-1581
The 99th Percentile Is Assay-specificAssays Available in the U.S.
Abb
ottA
RC
HIT
EC
TcT
nI
Roc
heco
bas
Ie60
1cT
nT4t
h-ge
n
OC
DV
ITR
OS
Eci
cTnI
ES
Abb
otti
STA
TcT
nI
Sie
men
sS
tratu
sC
ScT
nI
99th
perc
entil
e
400
375100
75
50
25
0
Bec
kman
Acc
uTnI
+3
Roc
heco
bas
Ie60
1cT
nI
Sie
men
sA
DV
IAC
enta
urTn
I-Ultr
a
Sie
men
sD
imen
sion
EXL
LOC
IcTn
I
Sie
men
sD
imen
sion
Vist
aLO
CIc
TnI
Ale
reTr
iage
Car
dio3
cTnI
ng/L
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 24 December 2015 A91DX-CAI-151429-UC1-4A00
Analytic Performance Varies among cTn Assays (2009)
Designation of cardiac troponin assaysAcceptance designation Total imprecision at the 99th percentile, CV%Guideline acceptable <10Clinically usable >10 to <20Not acceptable >20
Apple FS. Clin Chem 2009;55:1303-6.
“A New Season for Cardiac Troponin Assays:It’s Time to Keep a Scorecard”
Clin Chem, 2009
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 25 December 2015 A91DX-CAI-151429-UC1-4A00
Definition of various cardiac troponin assays
Conventional (clinically notusable)
No 99th percentile or>20% CV at the 99th percentile
Contemporary-sensitive Guideline acceptable(<10% CV at the 99th percentile)
High-sensitive Guideline compliant(<10% CV at 99th percentile) ANDdetects >50% of a healthy reference population usingLoD.
All assays Clinically usable(10-20% CV at the 99th percentile)
Defining Terms with cTn
Apple FS. Clin Chem 2009;55:1303-6.
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 26 December 2015 A91DX-CAI-151429-UC1-4A00
Type Company Platform Low End AssayRange µg/L
99th Percentileµg/L
CV% at 99thPercentile CV 10% µg/L Ratio CV 10% /
99th Percentile
Central Lab Siemens ADVIA Centaur® 0.0060* 0.040 8.8% 0.030 0.75
POC Siemens Stratus® CS System 0.0300* 0.070 8.2% (0.067) 0.060 0.86
Central Lab Siemens Dimension Vista® System 0.0150* 0.045 <10% 0.040 0.89
Central Lab Siemens Dimension® EXL™ System 0.0170† 0.056 <10% 0.050 0.89
Central Lab Ortho VITROS ECi ES 0.012† 0.034 10% 0.034 1.00
POC Mitsubishi PATHFAST cTnl-ll 0.007* 0.029 5% 0.014 0.48
Central Lab Abbott ARCHITECT 0.009* 0.028 14% 0.032 1.14
POC Abbott i-STAT 0.020* 0.080 17% 0.100 1.25
Central Lab Roche Elecsys (TnI) 0.160† 0.160 NA 0.300 1.88
Central Lab Siemens Dimension RxL 0.050* 0.070 20% 0.140 2.00
Central Lab Beckman UniCel DxI AccuTnI +3 0.010† 0.03 20% 0.04 1.33
Central Lab Beckman Access AccuTnI +3 0.010† 0.02 20% 0.04 2.00
Central Lab Roche Elecsys (TnT gen 4) 0.010* 0.010 NA 0.030 3.00
POC Alere Triage Cardiac 0.050* <0.050 NA NA NA
Analytical Characteristics of Troponin Assays
*Analytical sensitivity †Limit of detection (LoD)
Gu
idelin
eA
cceptab
leC
linically
Usab
le
Adapted from Apple. Clinical Chemistry. 2012;58:1; updated 2014
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 27 December 2015 A91DX-CAI-151429-UC1-4A00
AMIDiagnosis
Less-sensitive cTnGuideline-compliantsensitive cTn
Impact of Assay Type on Patient Care
What data suggestsclinical inequality?
Korley FK, Jaffe AS. J Am Coll Cardiol 2013;61:1753-8.
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 28 December 2015 A91DX-CAI-151429-UC1-4A00
AHA/ACC Guidelines for Management of NSTEMI
• Serial cTn should be obtained at presentation and at 3–6 hours. Assess changevalue in cTn (rising or falling pattern) using the 99th percentile and >20% change.
• Additional cTn testing beyond 6 hours if time of symptomonset is unclear or if clinical suspicion for MI remains.
• “Clinicians should be aware of the sensitivity of the tests used for troponinevaluation in their hospitals and cut-point concentrations for clinical decisions.”
• “Depending on the assay, values may not become abnormal for up to 12 hours.”Amsterdam EA, et al. Circulation 2014;130:e344-426.
“2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: A Report of the American College ofCardiology/American Heart Association Task Force on Practice Guideline”
Circ, 2014
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 29 December 2015 A91DX-CAI-151429-UC1-4A00
Why Serial Testing?
Serial testing can aid differentiation of an elevated cTnI resulting from an AMIfrom other causes of chronic cTnI elevation.
This is especially important when using sensitive/high-sensitive cTn assays.
Time since symptom onset (days)0 0 1 2 3 4 5 6 7
50
100
125
1020
Cutoff (99th percentile)
Draw 1
Draw 2
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 30 December 2015 A91DX-CAI-151429-UC1-4A00
0
20
40
60
80
100
120
140
160
180
200
0 hr 3 hr 6 hr 9 hr
Impact of Troponin Precision on Significant ChangeTr
opon
in(n
g/L)
Significant Change
No Significant Change40
80
150
OVERLAP
80
Guideline Acceptable10% CV @ 99th Percentile
Clinical Useable20% CV @ 99th Percentile
A guideline acceptabletroponin assay could
potentially show a significantchange at 3 hrs as opposed to6 hrs for a clinically useableassay thereby expediting the
diagnosis of myocardialinfarction.
An early diagnosis ofmyocardial infarction
facilitates rapid decisionmaking and treatment and
therefore improves theoutcome in patients
presenting with symptoms ofchest pain.
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 31 December 2015 A91DX-CAI-151429-UC1-4A00
Is It an MI? Rapid Risk Stratification Using Sensitive cTnI (Siemens DimensionEXL Assay)
Accelerated risk stratification of patients with ACS symptoms may occur at 2 hpost-presentation using troponin results measured by a sensitive* assay.”
*Sensitive cTn assay used was Siemens Dimension EXL LOCI cTnI.
“Incorporation of such strategy could support improvements in patient flow within emergency departments.”
*Similar results were found using a longer 0 and 6 hour testing strategy with the Beckman Accu TnI assay
Cullen L, et al. Heart Lung Circ 2014;23:428-34.
“Performance of Risk Stratification for Acute Coronary Syndrome withTwo-hour Sensitive Troponin Assay Results”
Heart Lung Circ, 2014
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 32 December 2015 A91DX-CAI-151429-UC1-4A00
Earlier Rule-out with Sensitive, Guideline Acceptable Assays?
“When used in conjunction with other clinical information including the ECG, a simplealgorithm incorporating s-cTnI* values at presentation and after 1 h (or 2 h) will allow safe rule-out and accurate rule-in of AMI in the majority of patients.”
Note: 41.5% (n = 901) were defined as “early presenters” (chest pain onset <3 h) and 58.5%(n = 1272) had chest pain onset >3 h.
*s-cTnI assay used was the Siemens TnI-Ultra.
Druey S, et al. Int J Cardiol 2015;195:163-70.
“Early Rule-out and Rule-in of Myocardial Infarction Using SensitiveCardiac Troponin I”
Int J Cardiol, 2015
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 33 December 2015 A91DX-CAI-151429-UC1-4A00
Earlier Rule-out with Sensitive, Guideline Acceptable Assays?
“Although the achieved NPVs for the 1 h and 2 h algorithmswere very high, it is important to highlight that they should onlybe used clinically in conjunction with full clinical assessmentincluding patient history and exam, and the 12-lead ECG.”
“30-day mortality was 0.2% for patients assigned to the rule-out zone,further documenting the safety of this approach and the suitability ofmany of these patients for early discharge.”
“The 1 h/2 h algorithms assigned 70% of patients a definite process(either rule-out or rule-in), with 30% of patients remaining in theobservational zone.”
Druey S, et al. Int J Cardiol 2015;195:163-70.
“Early Rule-out and Rule-in of Myocardial Infarction Using Sensitive Cardiac Troponin I”Int J Cardiol, 2015
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 34 December 2015 A91DX-CAI-151429-UC1-4A00
Important Aspects of Cardiac Troponin Testing
Sensitivity varies tremendously among commercially available cTn assays.
Sensitivity of the tests used for troponin evaluation in their hospitals and cut-pointconcentrations for clinical decisions difffer.
Depending on the assay or time of presentation, values may not become abnormalfor up to 12 hours.
Late presenters may not demonstrate a significant serial change if near the peak, orif troponin levels have declined.
Apple FS. Clin Chem 2009;55:1303-6.Amsterdam EA, et al. Circulation 2014;130:e344-426.Wildi K, et al. Clin Biochem 2015;48:218-22.
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 35 December 2015 A91DX-CAI-151429-UC1-4A00
Take Home Messages
üTroponin assays differ numerically due to:üStandardizationüDetection antibodies (assays detect different fragments)
üNumerical values DO NOT correlate with the sensitivity of the assay
ü Improved sensitivity of troponin assays translates to:#1 smaller areas of necrosis are detectable#2 earlier detection following injury#3 shorter serial testing protocols
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 36 December 2015 A91DX-CAI-151429-UC1-4A00
AMIDiagnosis
High-Sensitive cTnSensitive cTn
Impact of Assay Type on Patient Care
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 37 December 2015 A91DX-CAI-151429-UC1-4A00
2014: IFCC Task Force on How to Define High Sensitivity
99th percentile cutoff universally endorsed:• Determined in a healthy population.
• Derived from peer-reviewed literature ormanufacturer.
• Analytical precision should be ≤10% CV.
Guideline Acceptable (Sensitive) Assay:
• High-sensitivity assays (hs assays) shouldmeasure cTn >limit of detection (LoD) in ≥50%of the healthy subjects used to determine the99th percentile.
• Results reported in ng/L or pg/mL instead of µg/L(gives whole-number values instead of decimalsfor easier interpretation).
High-sensitive Assay Should be GuidelineAcceptable AND:
Apple FS, et al. Clin Biochem 2015;48:201-3.Apple FS, et al. Clin Chem 2007;53:547-51.
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 38 December 2015 A91DX-CAI-151429-UC1-4A00
cTn and Assay Sensitivity
“Sensitiveʼ and ʻhigh-sensitiveʼ are terms often used by manufacturers to describe theirassays for marketing purposes.”
Thygesen K, et al. Eur Heart J 2012;33:2252-7.
“How to Use High-sensitivity Cardiac Troponins in Acute Cardiac Care”Eur Heart J, 2012
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 39 December 2015 A91DX-CAI-151429-UC1-4A00
Don’t Rely on the Name of an Assay
“How a ‘high-sensitivity’ assay is defined has yet to be universally accepted.”
“It is important not to be influenced by the marketed name of the assay but instead relyon the performance characteristics of the assay.”
Apple FS, Saenger AK. Clin Chem 2013;59:1014-6.
“The State of Cardiac Troponin Assays: Looking Bright and Moving inthe Right Direction”
Clin Chem, 2013
Page 40A91DX-160289-XC1-4A00 Jennings/Soreng/Shalhoub/Levy Global MarketingRestricted © Siemens Healthcare, 2016 All rights reserved.
HS assays detect 50% ormore of healthy people >LoD
AMI and the 99th Percentile of a Normal Healthy Reference Population
100%
%P
opul
atio
nD
istri
butio
n
cTn LevelHealthy AMI or Other Pathology
CV of <10% at the99th percentileLoB
LoD
50th percentile
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 41 December 2015 A91DX-CAI-151429-UC1-4A00
The Problem: How Do You Define a Normal “Healthy” Reference Population?
Screening method for “healthy”?• Questionnaire?• Clinical testing?Age range?
Gender?
Ethnicity?
No uniform guidelines.
Each manufacturer and study uses adifferent reference population.
Sandoval, et al. Clin Chem. 2014;60(3):455-62.
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 42 December 2015 A91DX-CAI-151429-UC1-4A00
Increasing Sensitivity of cTn Assays Enables Detection of SmallerAreas of Necrosis
Troponin sensitivity: Does analytically more sensitive always mean an improvement clinically?
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 43 December 2015 A91DX-CAI-151429-UC1-4A00
Current “Sensitive” cTn Assays
Conclusion“The diagnostic performance of sensitive cardiac troponin assays is excellent, and these assays cansubstantially improve the early diagnosis of acute myocardial infarction, particularly in patients with arecent onset of chest pain.”
Reichlin, et al. NEJM. 2009;361:858-67.
Early Diagnosis of Myocardial Infarction WithSensitive Cardiac Troponin Assays
NEJM, 2009
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 44 December 2015 A91DX-CAI-151429-UC1-4A00
Most Sensitive and High Sensitive Assays Have ComparableDiagnostic Accuracy
Reichlin, et al. NEJM. 2009;361:858-67.
99th percentilecutoff
40 ng/L
28 ng/L
14 ng/L
160 ng/L
35 ng/L(10% CV)
SiemensTnI-Ultra
AbbottArchitectcTnI
Roche hs-cTnT
RochecTnI
Roche 4thgen cTnT
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 45 December 2015 A91DX-CAI-151429-UC1-4A00
Sensitive vs. High-Sensitive cTn in AMI Diagnosis
Compared:• Abbott hs-cTnI• Roche hs-cTnT• Siemens TnI-Ultra• Siemens Stratus cTnI• Beckman Accu Tni+3
Note: In this study, they refer to Siemens and Beckmanassays as “contemporary.”
Samples tested at 0 and 90 minutes post-admission.
Collinson PO, et al. Clin Biochem 2015;48:275-81.
“The Clinical and Diagnostic Performance Characteristics of the High-Sensitivity Abbott Cardiac Troponin I Assay”
Clin Biochem, 2015
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 46 December 2015 A91DX-CAI-151429-UC1-4A00
Sensitive vs. High Sensitive cTn in AMI Diagnosis
Admission and peak samples for Abbott’s hs-cTnI assay were statistically indistinguishablefrom the other troponin assays (AUC 0.90–0.94).Use of gender-specific cut points reduced thesensitivity for males but increased the sensitivityfor females.
Collinson PO, et al. Clin Biochem 2015;48:275-81.
“The Clinical and Diagnostic PerformanceCharacteristics of the High-Sensitivity Abbott
Cardiac Troponin Assay”Clin Biochem, 2015
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 47 December 2015 A91DX-CAI-151429-UC1-4A00
Study of cTnI Sensitivity from Harvard Medical School
Compared a current sensitive assay (Siemens TnI-Ultra) to an investigational hs-cTnI assay(Singulex) and a less-sensitive (“local”) cTnI (previous-generation Siemens cTnI).
“A contemporary sensitive assay delivered similar overall accuracy to the investigational test,suggesting that we have reached a point of maximum diagnostic return with increasing analyticalsensitivity.”
Bonaca MP, et al. European Heart Journal Acute Cardiovascular Care 2013;2:195-202.
“Evaluation of the Diagnostic Performance of Current and Next-GenerationAssays for Cardiac Troponin I in the BWH-TIMI ED Chest Pain Study”
Eur Heart J: Acute CV Care, 2013
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 48 December 2015 A91DX-CAI-151429-UC1-4A00
Study of cTnI Sensitivity from Harvard Medical School
Bonaca MP, et al. European Heart Journal Acute Cardiovascular Care 2013;2:195-202.
“Evaluation of the Diagnostic Performance of Current and Next-GenerationAssays for Cardiac Troponin I in the BWH-TIMI ED Chest Pain Study”
Eur Heart J: Acute CV Care, 2013
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 49 December 2015 A91DX-CAI-151429-UC1-4A00
High Sensitivity Impacts Specificity
“It is undeniable that the leading drawback of HS immunoassays
is represented by the lower specificity for diagnosing ACS. With
awareness of this limitation, the use of serial sampling is virtually
irrenunciable for increasing the positive-predictive value of HS methods.”
Lippi G, Cervellin G. Clin Chem Lab Med 2014;52:205-12.
“Do We Really Need High-Sensitivity Troponin Immunoassays in theEmergency Department? Maybe Not”
Clin Chem lab Med, 2014
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 50 December 2015 A91DX-CAI-151429-UC1-4A00
Sensitive vs. High Sensitive Assays and the Clinical Picture
• “Highly sensitive assays may, however, cause a diagnostic dilemma as to what to do withnewly detectable elevations that do not exceed the 99% MI cutoff.”
• “Although sensitive cTn assays do present an advantage compared to higher cut pointconventional assays, the benefit of higher sensitivity assays compared to sensitive assays inthe context of an MI diagnosis is unclear.”
Christenson E, Christenson RH. Ann Lab Med 2013;33:309-18.
“The Role of Cardiac Biomarkers in the Diagnosis and Management ofPatients Presenting with Suspected Acute Coronary Syndrome”
Ann Lab Med, 2013
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 51 December 2015 A91DX-CAI-151429-UC1-4A00
Preparing for the Implementation of hs-Assays*
1. Educate lab and clinical staff on relevant literature pertaining to the new assay
2. Understand that the concentration of troponin will change and will not involve aconversion factor
3. Establish a URL at the 99th percentile
4. Change from a single sex to a sex-specific 99th percentile
5. Report only whole numbers in ng/L
6. Define a QC material at the 99th percentile to monitor %CV*Apple FS, et al. Cardiac Troponin Assays: Guide to Understanding AnalyticalCharacteristics and Their Impact on Clinical Care. Clin Chem 63:1, 73-81 (2017).
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 52 December 2015 A91DX-CAI-151429-UC1-4A00
Preparing for the Implementation of hs-Assays*
7. Consider using troponin values <LoD of the hs-assay as a potential rule-outcharacteristic
8. Provide serial testing protocols that consider earlier measurements, such asbaseline, 1.5, and 3 hours for diagnostic determinations
9. Educate clinicians that although an increased troponin is reflective ofcardiac damage but not for ischemic damage
10. Assure good preanalytical sampling as the hs-assays are so sensitivethat poor sample quality can be a problem
Apple FS, et al. Cardiac Troponin Assays: Guide to Understanding AnalyticalCharacteristics and Their Impact on Clinical Care. Clin Chem 63:1, 73-81 (2017).
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 53 December 2015 A91DX-CAI-151429-UC1-4A00
Summary: Sensitive and High Sensitive cTn for an AMI Diagnosis
• Both sensitive(guideline acceptable) and high-sensitive assays support rapid identification of anAMI.
• Less-sensitive assays can miss MIs.• Use the same assay to assess change.• Improved sensitivity of troponin assays translates
to:• Detection of smaller areas of necrosis• earlier detection following injury• shorter serial testing protocols
• High sensitive troponin assays are underdevelopment but are not yet available in the US
• Preparation and education of labs andclinicians will be needed prior toimplementation
• New protocols may be needed.
Unrestricted © Siemens Healthcare Diagnostics Inc. 2015 All rights reserved.Page 54 December 2015 A91DX-CAI-151429-UC1-4A00
Linda C. Rogers, PhD, DABCC, FACBSenior Clinical Consultant
Scientific & Clinical Affairs
Phone: (949)421-9101Email: [email protected]
Siemens Healthcare Diagnostics, a globalleader in clinical diagnostics, provideshealthcare professionals in hospital,reference, and physician officelaboratories and point-of-care settings
with the vital information required toaccurately diagnose, treat, and monitorpatients. Our innovative portfolio ofperformance-driven solutions andpersonalized customer care combine tostreamline workflow, enhance operationalefficiency, and support improved patientoutcomes.
Product availability may vary from countryto country and is subject to varyingregulatory requirements.